🔗 Share this article

While the United States continues making historic changes to its vaccination recommendations, an unexpected name has emerged somewhat surprisingly: Tracy Beth Høeg, a Danish American sports medicine doctor and epidemiologist who first made her name by casting doubt on COVID-19 shots in the global health crisis and has zeroed in on alleged deaths after COVID-19 vaccination in her short tenure at the US Food and Drug Administration (FDA).

Scheduled Shifts to Pediatric Vaccine Program

Agency leaders were set to unveil sweeping changes to the pediatric vaccine schedule in December, synchronizing the US with Denmark’s vaccine program, it is understood – a significant shift that would place the US at odds with much of the global community with insufficient data for public health gain. The planned update has been pushed back until the coming year.

In place of the top vaccines chief, Dr. Høeg is set to present at the meeting. She was newly appointed acting director of the FDA’s CDER, the fifth appointee to lead the center this year.

Consolidating Power at the FDA

The acting appointment could signify a closer partnership between the drug and vaccine divisions as Dr. Høeg and Dr. Prasad consolidate power at the agency – and it signals a increased emphasis upon reevaluating already-approved immunizations at the FDA.

Høeg has repeatedly called for halting certain childhood vaccine recommendations in the US to become more like Denmark, a country with universal health coverage and a population approximately the population of Wisconsin’s.

To date statements, she has continued to focus on vaccination policy – typically the domain of Prasad, head of the FDA’s Center for Biologics Evaluation and Research (CBER) – rather than pharmaceutical oversight.

Concerns Over Qualifications

Dr. Høeg has no obvious track record in drug development, oversight or management, which has been typical for former leaders of the CBER. She has worked at the FDA as a top consultant to the agency head and the vaccine center since earlier this year.

“It seems she lacks to have the necessary background” for running the drug-regulation department, said Dr. Jonathan Howard. “She’s never run a randomized controlled trial. She has no expertise in leading a large organization. She lacks background in pharmaceutical oversight.”

Previous commissioners of the center would “grasp legal statutes and the research of drug development”, commented a former acting FDA commissioner. “Clearly, she doesn’t have the sort of resume that former directors who headed CBER have had.”

CDER has an vast range of responsibilities at the agency, the former commissioner emphasized.

“The public just focuses on the innovative therapies, but the generic drug division authorizes a multitude of off-brand pharmaceuticals. There is also a biosimilars program, OTC medication office and so forth, and every single one need to be looked after,” Dr. Woodcock explained. “The area you neglect, that is precisely what that I always told people is going to bite you.”

Additionally, a major leadership component to the position, which supervises more than 5,000 personnel. “It’s a huge administrative position, if you execute it properly,” she concluded.

Response and Controversial Programs

In response to concerns about Høeg’s fitness for the role and whether this appointment represents increased cooperation among FDA leaders on immunizations, a representative said that the “concerns are based on flawed premises”.

“This background is consistent with the duties of her job,” the spokesperson said, citing the time Dr. Høeg spent counseling the FDA commissioner on “medication safety and oversight research, including computational safety modeling and shot safety tracking”.

As acting director, Høeg assumes responsibility for the commissioner’s recently launched priority voucher program, a controversial expedited drug-approval program that reportedly worried her former heads. “By what process are these therapies being picked for this fast-track system? Who makes the choices?” Howard questioned. “There is a lot of confidentiality occurring at the regulatory body right now.”

In general, he said, “the agency looks to be trending towards laxer regulations of all drugs, with the exception of immunizations.”

Established Past Work on Immunizations

Concerning immunizations, Høeg has a clearer, if problematic, past, Howard said. She released a research paper using unverified volunteer-provided data to estimate the frequency of myocarditis after Covid immunization. She consulted for the state of Florida top health official Dr. Joseph Ladapo, who reportedly have modified findings to indicate Covid vaccinations are riskier than they are.

Among her “policy goals” for the incoming government included altering guidelines for recently developed shots and ending “optional” vaccines, she stated after the election on a audio program. At the FDA, Høeg has allegedly proposed barring adolescent males from obtaining Covid vaccinations.

“She’s an all-around true believer who commences with her preconceived notions and works backwards to accommodate the data in a extremely deceptive, untruthful fashion,” Dr. Howard stated.

Gaining Influence and a “Push for Payback”

Høeg became part of fellow dissenters, {like|